Table 2.
Effect of 40 months of intervention of Omega-3 fatty acids on decline in creatinine–cystatin C-based kidney function in 2344 patients of the Alpha Omega Trial according to treatment group
| Treatment Groups | Creatinine–Cystatin C-Based eGFR (ml/min per 1.73 m2)a | |||
|---|---|---|---|---|
| Pretreatment (Mean±SD) | Post-Treatment (Mean±SD) | Decline (Mean±SD) | Treatment Effect Mean (95% CI)b | |
| Placebo (n=593) | 79.2±18.4 | 72.3±20.1 | −6.9±12.6 | |
| ALA (n=601) | 79.0±19.3 | 72.7±20.4 | −6.2±12.8 | 0.7 (−0.8 to 2.1) |
| EPA-DHA (n=576) | 78.2±18.5 | 73.4±19.2 | −4.8±13.4 | 2.1 (0.6 to 3.6) |
| EPA-DHA plus ALA (n=574) | 77.6±18.5 | 71.6±19.5 | −6.0±13.0 | 0.9 (−0.6 to 2.3) |
95% CI, 95% confidence interval.
a
On the basis of the Chronic Kidney Disease Epidemiology Collaboration equation of 2012 (15).
b
Decline in intervention group minus decline in placebo group with 95% CI.